Page last updated: 2024-09-05

opc 28326 and alprostadil

opc 28326 has been researched along with alprostadil in 1 studies

Compound Research Comparison

Studies
(opc 28326)
Trials
(opc 28326)
Recent Studies (post-2010)
(opc 28326)
Studies
(alprostadil)
Trials
(alprostadil)
Recent Studies (post-2010) (alprostadil)
9117,136864761

Protein Interaction Comparison

ProteinTaxonomyopc 28326 (IC50)alprostadil (IC50)
Multidrug resistance-associated protein 4Homo sapiens (human)2.3
Solute carrier organic anion transporter family member 2B1Rattus norvegicus (Norway rat)0.0358

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, R; Kambayashi, JI; Li, J; Lockyer, S; Sun, B; Yoshitake, M1

Other Studies

1 other study(ies) available for opc 28326 and alprostadil

ArticleYear
OPC-28326, a selective femoral vasodilator, is an alpha2C-adrenoceptor-selective antagonist.
    The Journal of pharmacology and experimental therapeutics, 2001, Volume: 299, Issue:2

    Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Alprostadil; Aniline Compounds; Animals; CHO Cells; Cloning, Molecular; Cricetinae; Femoral Vein; Hindlimb; In Situ Hybridization; In Vitro Techniques; Luciferases; Male; Piperidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Vasodilator Agents; Yohimbine

2001